• Tiếng Việtvi
  • Englishen
  • Oyster Area Pharma to present Analyses at Ladies in Ophthalmology Summer Symposium

    The reader is warned to not have confidence in such pass-searching statements

    PRINCETON, Letter.J., (Community NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-phase biopharmaceutical business focused on the fresh new knowledge, advancement, and you will commercialization regarding earliest-in-classification pharmaceutical therapies to alleviate ophthalmic ailment, now established this new demonstration regarding analyses on Ladies in Ophthalmology (WIO) Summer Symposium, that is taking place in Monterey, California out-of .

    “I look forward to the 2009 WIO June Symposium, a beneficial curated fulfilling for females offering articles in every subjects out-of importance so you can people ophthalmologists,” said Marian Macsai, MD head medical manager, Oyster Section Pharma. “With each other, new TYRVAYA® study our company is to present show surface when you look at the therapy perception which have a great tolerability and you may coverage reputation for people managing dead attention disease, a condition which is much more prominent in women.”

    Title: OC-01 (varenicline solution) Nose Spray for the treatment of Inactive Eye Disease Signs and you can Episodes during the Subjects having Autoimmune Situation: Incorporated Research out-of Start-step one and you will Beginning-2

    Title: Evaluation out-of OC-01 (varenicline service) Nasal Spraying 0.03mg Features Considering Menopause Condition: Post-hoc Data regarding Onset-step one and you will Start-dos Clinical Samples

    Oyster Section Pharma are a professional-stage biopharmaceutical business worried about the advancement, advancement and you will commercialization out of basic-in-category drug therapies to relieve ophthalmic infection. (more…)